sponsors our vision€¦ · 06 go to menu previous page next page vivek jha head of strategy and...

GET IN TOUCH WITH US:

Click here to find out whatour clients think about ourSTRATEGY MEETINGS

ONLINE ONCOLOGYSTRATEGY MEETING 2020

3rd November 2020, Tuesday 1:00pm - 6:00pm UK | 8:00am - 1:00pm EST

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com Connect with us

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: Biomarker Discovery

TRACK 2: Precision Medicine / Personalised Medicine

TRACK 3: Companion Diagnostics

TRACK 4: Antibody Discovery, Antibody Drug Conjugates

TRACK 5: Immuno-oncology / Check Point Inhibitors

TRACK 6: Clinical Research

2019 ATTENDEES

CONTRIBUTORS TO THE AGENDA

06619e

Mahendra DeonarainCEO/CSOAntikor Biopharma

Maziar AssadiDirectorBasilea

Vivek JhaHead of Strategy and Operations, Global Drug DevelopmentNovartis

OM SharmaSenior DirectorDSI

Lore GruenbaumVP, Research Therapy Acceleration ProgramThe Leukemia & Lymphoma Society

Yu LiangDirector, Translational Sciences, OncologyIpsen

Agamemnon EpenetosProfessorHarley Street Clinic

Aleksandra FilipoviHead of OncologyPuretech Health

OUR UNIQUE ONLINE MEETING FORMATRoundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

Innovative SolutionsWhatever your challenge may be, let our official event partners find the solution. Gain access to our carefully selected solution providers and find your next strategic partner that will help take your business to the next level.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

OUR VISION

OUR MISSION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

https://proventainternational.com/testimonials/

mailto:info%40proventainternational.com?subject=

https://proventainternational.com/

https://www.facebook.com/proventainternational

https://twitter.com/proventaintl

https://www.linkedin.com/company/proventa-international/

https://www.youtube.com/channel/UCwbeSVlm92MnddSH05XXcTA

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com

SPONSORSOUR

02GO TO MENU PREVIOUS PAGE NEXT PAGE


PRO-PARTNERS

EXHIBITORS

At PerkinElmer Informatics, our focus is on redefining how labs in Pharma, Biotech, Chemicals and major academic centers embrace electronic data capture, cloud-based applications and collaborative tools to manage and analyze their data. With our cloud based collaboration solutions and powerful visual analytics platforms, critical scientific data transforms into actionable insights in an automated, predictive and scalable way. Our solutions include the industry leading ChemDraw application, robust ELN, advanced analytics powered by TIBCO® Spotfire and the Signals Platform. The cloud based PerkinElmer SignalsTM platform unlocks the hidden knowledge within your scientific data whether you are working independently or collaboratively with solutions for Translational Medicine, Screening, Lead Discovery, and Biologics.

Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems.

ONTOFORCE empowers data-driven decisions, drives innovation and speeds-up cycle time. We unlock and connect siloed data into a linked data fabric. This enables everyone to securely integrate, analyze, and extract data faster, bringing simplicity to complexity. With DISQOVER, ONTOFORCE developed an innovative, self-service, linked data platform that delivers trusted and timely insights for end users.

CO-HOST SPONSORSARENSIA EXPLORATORY MEDICINE is a German operator of proprietary Research Clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world’s largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies.



https://exploristics.com/

https://biocytogen.com/

https://www.tamirna.com/

https://guardanthealth.com/

https://www.mablink.com/

http://immune-insight.com/

https://atoz-cro.de/

http://www.birdotech.com/

https://www.perkinelmer.com/

https://www.cmedresearch.com/

https://www.ontoforce.com/

https://www.arensia-em.com/


AGENDATRACK & ROOM

(TIME - UK) 01 - BIOMARKER DISCOVERY 02 - PRECISION MEDICINE / PERSONALISED MEDICINE

03 - COMPANION DIAGNOSTICS

04 - ANTIBODY DISCOVERY, ANTIBODY DRUG CONJUGATES

05 - IMMUNO-ONCOLOGY / CHECK POINT INHIBITORS 06 - CLINICAL RESEARCH

1:00pm - 1:30pm UK KEYNOTE PRESENTATION

1:30pm - 1:45pm UK BREAK

1:45pm - 2:45pm UK

Shifting Towards Protein-Based Diagnostic Biomarkers and Effectively Utilising Assays to Determine Genetic Mutations Maziar Assadi — Director, Basilea

Strategies to detect low levels of ctDNA in liquid biopsies Vivek Jha — Head of Strategy and Operations, Global Drug Development, Novartis

How do we define companion diagnostics and effectively utilise them in treatment selection? Agamemnon Epenetos — Professor, Harley Street Clinic

Overcoming limitations of linkage and conjugation chemistry to link an optimized number of the payloads to the antibody in predefined location homogeneously. OM Sharma — Senior Director, DSI

Will we ever reach the goal of an allogeneic off-the-shelf T cell immunotherapy or should be we driving toward optimising autologous therapies? Aleksandra Filipovi — Head of Oncology, Puretech Health

Increasing patient reach whilst maintaining retention for complex oncology trials and dealing with intense competition for patient populations Lore Gruenbaum — VP, Research Therapy Acceleration Program, The Leukemia & Lymphoma Society


3:00pm - 4:00pm UK

Strategies to Implement and Validate More Biomarkers from Discovery Into Clinical Practise Title TBC

Establishing a better understanding and utilization of correlations betweens non-genetic and genetic factors which contribute to different cancer phenotypes Title TBC

Strategies to increase clinical implementation of precision medicine companion diagnostics Title TBC

Selecting and optimising the most suited stable linkers and cytotoxic agents for ADC therapeutics Title TBC

Optimising autologous T cell immunotherapies - reducing vein-to-vein time and cost Title TBC


4:15pm - 4:45pm UK KEYNOTE PRESENTATION KEYNOTE PRESENTATION


5:00pm - 6:00pm UK

Integrating Multi-Omics Data With New in silico Technologies to Drive Biomarker Discovery Yu Liang — Director, Translational Sciences, Oncology, Ipsen

Increasing mutation detection rate in targeted therapies

Improving CDx Assay Sensitivity to Detect Low Levels of Biomarkers

Discovering and Engineering Better Antibody Therapeutics Using Innovative in silico Technologies Mahendra Deonarain — CEO/CSO, Antikor Biopharma

With new innovations in immuno-oncology are checkpoint inhibitors a thing of the past?

How can we make oncology trials more systematic, streamlined and efficient whilst keeping the already high costs down

END






KEYNOTE PRESENTATION


SpeakerTBC

Topic TBC

1:00pm - 1:30pm UK 4:15pm - 4:45pm UK

1ST KEYNOTE PRESENTATION

ARENSIA EXPLORATORY

MEDICINE

Topic TBC

2ND KEYNOTE PRESENTATION





TRACK 1Biomarker Discovery


Maziar Assadi DirectorBasilea

Yu LiangDirector, Translational Sciences,

OncologyIpsen

Shifting Towards Protein-Based Diagnostic Biomarkers and Effectively Utilising Assays to Determine Genetic Mutations

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Strategies to Implement and Validate More Biomarkers from Discovery Into Clinical Practise

SPONSOR

Integrating Multi-Omics Data With New in silico Technologies to Drive Biomarker Discovery





TRACK 2Precision Medicine /

Personalised Medicine


Vivek JhaHead of Strategy and Operations,

Global Drug DevelopmentNovartis

SpeakerTBC

Strategies to detect low levels of ctDNA in liquid biopsies

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Establishing a better understanding and utilization of correlations betweens non-genetic and genetic factors which contribute to different cancer phenotypes

SPONSOR

Increasing mutation detection rate in targeted therapies





TRACK 3Companion Diagnostics


Agamemnon EpenetosProfessor

Harley Street Clinic

SpeakerTBC

How do we define companion diagnostics and effectively utilise them in treatment selection?

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Strategies to increase clinical implementation of precision medicine companion diagnostics

SPONSOR

Improving CDx Assay Sensitivity to Detect Low Levels of Biomarkers





TRACK 4Antibody Discovery,

Antibody Drug Conjugates


OM Sharma Senior Director

DSI

Mahendra DeonarainCEO/CSO

Antikor Biopharma

Overcoming limitations of linkage and conjugation chemistry to link an optimized number of the payloads to the antibody in predefined location homogeneously

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Selecting and optimising the most suited stable linkers and cytotoxic agents for ADC therapeutics

SPONSOR

Discovering and Engineering Better Antibody Therapeutics Using Innovative in silico Technologies





TRACK 5Immuno-oncology /

Check Point Inhibitors


Aleksandra FilipoviHead of Oncology

Puretech Health

SpeakerTBC

Will we ever reach the goal of an allogeneic off-the-shelf T cell immunotherapy or should be we driving toward optimising autologous therapies?

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Optimising autologous T cell immunotherapies - reducing vein-to-vein time and cost

SPONSOR

With new innovations in immuno-oncology are checkpoint inhibitors a thing of the past?





TRACK 6Clinical Research


Lore GruenbaumVP, Research Therapy Acceleration ProgramThe Leukemia &

Lymphoma Society

SpeakerTBC

Increasing patient reach whilst maintaining retention for complex oncology trials and dealing with intense competition for patient populations

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

Cmed

With increases in autologous immunotherapies and gene therapies how can we reduce long and frequent site visits and increase patient centricity - Title TBC

SPONSOR

How can we make oncology trials more systematic, streamlined and efficient whilst keeping the already high costs down




UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com 11

2019 ATTENDEES

GO TO MENU PREVIOUS PAGE

COMPANY JOB TITLEABPI Head of Health Data & OutcomesAIT Austrian Institute of Technology GmbH

Thematic Coordinator

Alkol Biotech CEOAmgen European RWD leadAmgen Programming Lead for Europe, Centre for Observational

ResearchAmgen DirectorArtios Pharma Principal Scientist, BioinformaticsAstraZeneca Global Head of Health InformaticsAstraZeneca Health Informatics DirectorAstraZeneca Principal ScientistAstraZeneca Principal Data ScientistAstraZeneca Senior Director, Knowledge ManagementAstraZeneca Associate Director, BioinformaticsAstraZeneca Associate Principal Informatics ScientistAstraZeneca Programme Manager, Clinical Information SharingBar Ilan University Professor/DirectorBayer AG Clinical Development LeadBiogen Head of Computational ChemistryBiogen Medical Director, EU & Canada Medical Strategy &

Execution LeadBiomedical Research Centre at Guy’s

Head of Genomics Research Platform and Single Cell Facility

Hospital and King’s College London

and Senior Research Fellow

Biozentrum, University of Basel

Head Research IT

Bluebird bio Associate Director Medical AffairsBlueprint Medicines International Head of Precision MedicineBoehringer Ingelheim Clinical Program LeadBridge Biotec Ltd Director / CEOBrunel University London Senior LecturerC4x Discovery Target Discovery Genetics Project LeaderC4x Discovery VP Novel Target Biology & GenomicsCoordination Centre for Clinical Trials (KKS)

Director

Debiopharm International VP Translational MedicineE Therapeutics PLC Business Development and Programme DirectorEli Lilly Lead Senior BioinformaticianEli Lilly Senior BioinformaticianErasmus MC ProfessoreTherapeutics Principal Data ScientistFraunhofer ITEM Group LeaderGalapagos Head of BioinformaticsGenomics England Head of Bioinformatics PartnershipsGlaxoSmithKline Global Head Computational Biology and StatsGlaxoSmithKline Scientific LeaderGlenmark Pharmaceuticals Senior Vice President, Global Head of Translational

Sciences

COMPANY JOB TITLEGoldsmiths, University of London Professor of Cognitive Computing

Grünenthal Scientific DirectorGSK Senior Scientific DirectorGSK Senior MetaData ManagerGSK Interim Head of Human Genetics Computational BiologyGSK Senior MetaData ExpertGSK Science Advisor Gene Therapy and Rare DiseaseHiFiBio EVP Business DevelopmentImmatics Biotech Director, Clinical DevelopmentImperial College London Research FellowImperial College London Professor/ Director CISBIOInflaRx CMOInflaRx Program Director Clinical Research & Development

OncologyIO Biotech Chief Medical OfficeriOnctura SA Chief Operating OfficerIpsen Vice President Translational Sciences & Clinical

PharmacologyIpsen Medical DirectorJanssen Medical Manager OncologyJuno Therapeutics, a Celgene company

Senior Vice President and Managing Director

Karus Therapeutics Chief Operating Officer and Chief Scientific OfficerKing’s College London Director of eResearchKymab Senior Scientist (KY1005 Scientific Lead) , Transnational

MedicineLeo Pharma Principal ScientistLondon South Bank University Professor, Head of Big Data and Informatics Research

GroupMax Planck Institute for Biology of Ageing

Head of Bioinformatics

Medigene Immunotherapies GmbH

Director

MedImmune VP Clinical RespiratoryMerck Director Cancer & Inflammation, Scientific Site Head

Immuno-OncologyMerck KGaA Director Oncology BioinformaticsMerck KGaA Market Access Lead Oncology EMEAMerck KGaA Director, Clinical Quality ManagementMerck KGaA Senior Director, Head Biomarker Development & Validation

StrategyMerck Sharp & Dohme Director, R&D AnalyticsMerus Executive Vice President and Chief Scientific OfficerMolecular Partners, AG VP, Head of Immuno-oncologyMorphoSys Director, Program LeaderMorphoSys Vice President & Head of CommercialNanna Therapeutics Director of InformaticsNektar Therapeutics Vice President and Head of DiscoveryNeovii Pharmaceuticals Chief Scientific Officer

COMPANY JOB TITLENovartis Data Science Head MusculoskeletalNovartis Head of Medical Affairs ORENovartis Medical Systems Head - ICE, Global Medical AffairsNovozymes Head of IT DepartmentOncoOne CEOOncoQR ML Chief Scientific Officer and Managing DirectorOxford BioTherapeutics Director of Information Systems and BioinformaticsOxford BioTherapeutics Chief Executive OfficerPhilochem Global Head of Precision MedicinePieris Director Immuno OncologyPierre Fabre Vice President – Head of Translational MedicineProthena EU Medical Affairs headQueen Mary University Professor and Director, Centre for Translational

BioinformaticsRoche Global Head Strategic Alliances PREDiRoche Head of Global BI Solution Center WelwynRoche Digital Lead for Large Molecule ResearchRoche Director External Innovation, Oncology DiscoveryRoche Global Medical DirectorRoche Global Studies LeaderRoche Diagnostics Head Data ManagementRoche Pharma Senior LeaderSandoz International Head Strategy and Novartis CollaborationsSanofi Sr Director, European Head of Medical Affairs for

Oncology, Hematology and Solid Organ TransplantationSanofi Medical Manager Oncology GSAServier Head of Bioinformatics and Computational BiologyServier Head of Global Oncology Early Products StrategyServier Deutschland GmbH Director BU Oncology / HematologyShire Global Medical LeadTakeda Scientific Informatics ArchitectThemis Biosciences Head ImmunotherapyTYG Oncology Chief Executive Officer and Co-FounderUCB Director, Translational Bioinformatics, NeurosciencesUCB Head of IT, New Medicines InnovationUCL Academic Lead of UCL GenomicsUniversität zu Lübeck, Medical Systems Biology

Group Leader

University College London Professor of Bioinformatics and Computational BiologyUniversity of Basel Project HeadUniversity of Buckingham Interim Dean – School of ComputingUniversity of Cambridge Head of Bioinformatics CoreUniversity of Halle-Wittenberg Group LeaderUniversity of Leipzig Deputy HeadUniversity of Lübeck Professor for Systems MedicineUniversity of Munich Private ProfessorUniversity of Plymouth Professor in BioinformaticsVertex Pharmaceuticals Director, Scientific Computing




sponsors our vision€¦ · 06 go to menu previous page next page vivek jha head of strategy and...

Documents